Ming‐Feng Hou
Impact in
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- MicroRNA in disease regulation
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Cancer Cells and Metastasis
Papers in
-
- Breast Cancer Treatment Studies 61
- Cancer, Lipids, and Metabolism 9
- Oncology 86
- Cancer Cells and Metastasis 19
- Cancer survivorship and care 13
- Co-authors
- Hsueh‐Wei Chang (37 shared papers)Pei‐Yi Chu (22 shared papers)Shyng‐Shiou F. Yuan (43 shared papers)Jen‐Yang Tang (26 shared papers)Wen‐Chun Hung (14 shared papers)Chia‐Jung Li (10 shared papers)Eing‐Mei Tsai (26 shared papers)Hurng‐Wern Huang (9 shared papers)
- Journals
- International Journal of Molecular Sciences (13 papers)PLoS ONE (12 papers)Oncology Reports (8 papers)Breast Cancer Research and Treatment (8 papers)Cancers (8 papers)
- Partner nations
- TaiwanUnited StatesUnited Kingdom
In The Last Decade
Ming‐Feng Hou
396 papers receiving 15.9k citations
Ming‐Feng Hou's Hit Papers
Peers
Comparison fields: 5 of 171
- Cancer Research 3.4k
- Oncology 2.9k
- Genetics 2.8k
- Endocrine and Autonomic Systems 416
- Molecular Biology 2.8k
Countries citing papers authored by Ming‐Feng Hou
This map shows the geographic impact of Ming‐Feng Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Feng Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Feng Hou more than expected).
Fields of papers citing papers by Ming‐Feng Hou
This network shows the impact of papers produced by Ming‐Feng Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Feng Hou. The network helps show where Ming‐Feng Hou may publish in the future.
Co-authors
The 25 scholars most cited alongside Ming‐Feng Hou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 405 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Hit paper breakdown → | 2012 | 1568 |
| 2 | Association analysis identifies 65 new breast cancer risk loci Hit paper breakdown → | 2017 | 1040 |
| 3 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer Hit paper breakdown → | 2015 | 489 |
| 4 | Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial Hit paper breakdown → | 2020 | 489 |
| 5 | 2017 | 469 | |
| 6 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Hit paper breakdown → | 2013 | 468 |
| 7 | 2005 | 351 | |
| 8 | 2017 | 341 | |
| 9 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 10 | 2005 | 288 | |
| 11 | Marine algal natural products with anti-oxidative, anti-inflammatory, and anti-cancer properties Hit paper breakdown → | 2013 | 279 |
| 12 | 2018 | 190 | |
| 13 | 2016 | 160 | |
| 14 | 2011 | 144 | |
| 15 | 2005 | 140 | |
| 16 | 2014 | 127 | |
| 17 | 2006 | 117 | |
| 18 | 2010 | 113 | |
| 19 | 2013 | 104 | |
| 20 | 2016 | 103 |
About Ming‐Feng Hou
Ming‐Feng Hou is a scholar working on Cancer Research, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 405 papers that have together received 16.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (61 papers), Genetic Associations and Epidemiology (34 papers), BRCA gene mutations in cancer (20 papers), Cancer Cells and Metastasis (19 papers), Breast Lesions and Carcinomas (18 papers), Cancer survivorship and care (13 papers), Breast Implant and Reconstruction (11 papers) and Cancer, Lipids, and Metabolism (9 papers). The work is most often cited by research in Cancer Research (3.4k citations), Oncology (2.9k citations), Genetics (2.8k citations), Endocrine and Autonomic Systems (416 citations) and Molecular Biology (2.8k citations). Ming‐Feng Hou has collaborated with scholars based in Taiwan, United States and United Kingdom. Frequent co-authors include Hsueh‐Wei Chang, Pei‐Yi Chu, Shyng‐Shiou F. Yuan, Jen‐Yang Tang, Wen‐Chun Hung, Chia‐Jung Li, Eing‐Mei Tsai, Hurng‐Wern Huang, Fu Ou‐Yang and Po‐Lin Kuo. Their work appears in journals such as International Journal of Molecular Sciences, PLoS ONE, Oncology Reports, Breast Cancer Research and Treatment and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.